Prevalence of cystic fibrosis mutations in the Grampian region of Scotland

Zofia H Miedzybrodzka, John C S Dean, George Russell, James A R Friend, Kevin F Kelly, Neva E Haites

Abstract
We have identified all known sufferers of cystic fibrosis (CF) alive in the Grampian region, north east Scotland, on 1 January 1989. DNA samples were obtained for a prevalence study of the common mutations with near to complete ascertainment. A relatively high prevalence of the ΔF508 mutation was found (82%), with one of four mutations being present on 92% of CF chromosomes. The high prevalence of these four easily detectable mutations in Grampian has local implications for genetic counselling, the efficacy of population carrier screening, and the usefulness of mutation analysis in cases where the diagnosis of CF is in doubt.

(J Med Genet 1993;30:316-17)

We have identified all known cystic fibrosis (CF) sufferers alive in the Grampian region, Orkney, and Shetland (population 545 000) on 1 January 1989 as part of a population study of north east Scotland.

Patients were identified from all possible sources including clinicians, local registers, and national computerised records. CF diagnosis required relevant clinical features and three positive sweat tests. DNA samples were obtained and tested for the mutations listed in the table using standard methods.7

A life table of age at diagnosis was constructed and used to estimate the proportion of cases alive on 1.1.89 whose diagnosis had not been made by 1.7.92 (17%). Results of mutation analysis are presented in the table. The proportion of AF508 CF chromosomes found (82%) was significantly greater than that reported previously for Scotland (71%, 95% confidence intervals 0.02 and 0.18).

The ΔF508 frequency among CF chromosomes of Grampian origin (grandparents) was not significantly different from that among chromosomes from outside Grampian (50/64 vs 21/24, χ² = 0.98).


<table>
<thead>
<tr>
<th>Mutation</th>
<th>No of CF chromosomes</th>
<th>Proportion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔF508</td>
<td>96</td>
<td>82.1</td>
</tr>
<tr>
<td>G551D</td>
<td>8</td>
<td>6.8</td>
</tr>
<tr>
<td>G542X</td>
<td>2</td>
<td>1.7</td>
</tr>
<tr>
<td>A1507</td>
<td>1</td>
<td>0.85</td>
</tr>
<tr>
<td>1717-1G-A</td>
<td>1</td>
<td>0.85</td>
</tr>
<tr>
<td>621+1G-T</td>
<td>1</td>
<td>0.85</td>
</tr>
<tr>
<td>R553X</td>
<td>1</td>
<td>0.85</td>
</tr>
<tr>
<td>R560T</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>R117H</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No mutation identified</td>
<td>7</td>
<td>6.0</td>
</tr>
<tr>
<td>Total</td>
<td>117</td>
<td>100.0</td>
</tr>
</tbody>
</table>

The calculated point prevalence, adjusting for cases in whom a diagnosis has not yet been made, was much higher (1/7100) than that reported for Britain (1/11 400), as was the calculated incidence (1/2260 vs 1/2500). These findings may reflect a higher gene frequency in Grampian, longer survival, or merely better ascertainment.

The proportion of CF chromosomes carrying the ΔF508 mutation in Grampian is significantly higher (82%) than that reported previously for a Scottish population (71%). That population was largely from south east Scotland, so both these frequencies fit the north west-south eastcline in ΔF508 frequency across Europe.8 Alternatively, our findings may reflect a founder effect, as has been shown in Brittany (80%) and the Basque country (87%).7

However, the origin of chromosomes in our study has no effect on ΔF508 frequency so our findings may reflect virtually complete ascertainment and careful exclusion criteria. All the CF chromosomes carrying G551D were of Grampian origin, which is in keeping with the hypothesis that it is a Celtic mutation.6

All CF patients in Grampian have at least one identifiable CF mutation, so we predict only 1 in 277 patients would have no detectable mutations (Hardy-Weinberg). This may be helpful in cases where the diagnosis of CF is in doubt.

Testing for four common mutations simultaneously (ΔF508, G551D, G542X, and 621+1G-T) can detect 92% of Grampian carriers, making carrier screening more efficient than might be expected from other studies (84% Scottish study, 83% Welsh study).6 Eighty-three percent of carrier couples are identified in contrast to 71% calculated from the Scottish study and 69% from the Welsh study.8 When the partner of a carrier tests negative for the above mutations, the couple’s residual risk of having an affected child is of the order of 1/1200 compared to 1/520.

Local knowledge of the prevalence of CF mutations is essential for good genetic counselling for CF families and before considering any population for screening. Any cost-benefit analysis of screening produced by studies from other areas should be considered in the context of the local prevalence of mutations.

Z Miedzybrodzka is currently funded by the Wellcome Trust and previously by a Scottish Hospitals Endowments Research Trust Cru- den Scholarship. This work was funded by Grampian Health Board and the Scottish Hos-

University of Aberdeen Department of Medicine and Therapeutics, Aberdeen, Z H Miedzybrodzka J C S Dean J A R Friend N E Haites

University of Aberdeen Department of Obstetrics and Gynaecology, Aberdeen, Z H Miedzybrodzka

University of Aberdeen Department of Child Health, Aberdeen, G Russell

University of Aberdeen Department of Molecular and Cell Biology, Aberdeen, K F Kelly N E Haites

Correspondence to: Dr Miedzybrodzka, Medical Genetics, Medical School, Foresterhill, Aberdeen AB9 2ZD.

Received 19 June 1992, Revised version accepted 9 September 1992.
pitals Endowments Research Trust. We are grateful to Ms Mona Abdulla for statistical help, Drs Tony Shrimpton and Steve Little for helpful advice, the European Community Concerted Action on Cystic Fibrosis for provision of control DNA and some oligonucleotides, Cellmark Diagnostics for provision of ARMS kits, and Dr Joe Legge for permission to enrol his patient in the study. We would also like to thank Elspeth Bruford, Mark Davidson, Gail Rettie, Alasdair Williamson, and Zhikang Yin for technical help.